NCT04190056 2023-08-31
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
University of California, San Francisco
Phase 2 Terminated
University of California, San Francisco
University of California, San Francisco
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins